Maraviroc advisory committee

Executive Summary

FDA's Antiviral Drugs Advisory Committee will meet April 24 to review Pfizer's potential first-in-class HIV therapy maraviroc, according to a notice in the Federal Register Feb. 7. Pfizer will market the CCR5 antagonist candidate with Monogram's co-receptor tropism assay Trofile to identify patients who are most likely to respond to the drug class (1"The Pink Sheet" Dec. 18, 2006, p. 11). The meeting will be held at the CDER advisory committee conference room, 5630 Fishers Lane, Rockville, Md., beginning at 8 a.m...